Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs EHang Holdings Ltd - ADR (EH) Price & Performance

ADMA Biologics IncTrade
EHang Holdings Ltd - ADRTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs EHang Holdings Ltd - ADR — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while EHang Holdings Ltd - ADR trades at $5.78 (market cap $435.35M). The key difference: ADMA Biologics Inc is far larger — about 5× EHang Holdings Ltd - ADR's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.

ADMAEH
Market Cap
$2.18B$435.35M
Sector
HealthIndustrials
52-Week High
$20.38$19.44
52-Week Low
$7.60$4.90
Enterprise Value
$2.25B$374.58M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

EHang Holdings Ltd - ADR

EHang Holdings (EH) trades at $5.74, up 7.69% in the last session, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported Q1 2026 revenue of $418 million, flat year-over-year, but with a significant net loss of $276 million, reflecting ongoing profitability challenges despite a high gross margin of 61.53%. Recent news highlights operational progress, including the first pilotless eVTOL flight in Central Asia, but the stock remains volatile amid sector-wide pressures.

The outlook for EH is highly speculative, with substantial execution risks and negative earnings overshadowing long-term potential in the advanced air mobility market. Analyst sentiment is divided, with a consensus price target of $6.97 offering limited upside, while institutional ownership trends and cash flow volatility underscore the high-risk nature of the investment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About EHang Holdings Ltd - ADR

EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

Read more on EH